Glucose homeostasis and insulin secretion during chronic treatment with cyclosporin in nondiabetic humans

R. P. Robertson, G. Franklin, L. Nelson

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

Cyclosporin or placebo was administered in a randomized, double-blind fashion to 13 patients with multiple sclerosis for 1 yr to determine whether cyclosporin adversely affects glucose homeostasis or β-cell function. No significant differences were observed in fasting glucose, fasting insulin, intravenous glucose tolerance, or glucose-induced insulin secretion before treatment or at 3 wk, 6 mo, or 1 yr during treatment. Longer therapeutic trials with larger patient groups will be necessary to decide whether cyclosporin can be safely given for many years without risk of developing diabetes mellitus.

Original languageEnglish (US)
Pages (from-to)99-100
Number of pages2
JournalDiabetes
Volume38
Issue numberSUPPL. 1
DOIs
StatePublished - 1989

Fingerprint

Dive into the research topics of 'Glucose homeostasis and insulin secretion during chronic treatment with cyclosporin in nondiabetic humans'. Together they form a unique fingerprint.

Cite this